A CLEAR CHOICE for Visible Results
See the visible impact on acne and its sequalae
AKLIEF® (triferotene) Cream, 0.005% is a clear choice for rapid reduction of acne on the face and trunk,¹ab while helping reduce and improve the visible effects of acne-induced scarring²c and post-inflammatory hyperpigmentation (PIH)*.³cd See what clearer skin could look like for your patients, and discover how AKLIEF Cream can help deliver results that go beyond active acne clearance.1,2,3abcd
See the difference in facial acne
The clinical images presented are from the Phase 3 pivotal studies evaluating AKLIEF Cream in patients with acne vulgaris. AKLIEF Cream delivered rapid improvements in facial acne. Patients achieved greater than 50% reduction in inflammatory lesions by Week 8 and up to 66.2% reduction by Week 12.¹ab
Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of AKLIEF Cream vs vehicle cream.1 IGA=Investigator's Global Assessment.
Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of AKLIEF Cream vs vehicle cream.1 IGA=Investigator's Global Assessment.
Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of AKLIEF Cream vs vehicle cream.1 IGA=Investigator's Global Assessment.
See proven results on the trunk
The clinical images presented are from the Phase 3 pivotal studies evaluating AKLIEF Cream in patients with acne vulgaris. AKLIEF Cream demonstrated efficacy across the chest, shoulders, and back, with significant improvements in truncal acne observed as early as Week 2 and up to a 66.4% reduction in truncal lesions by Week 12.1ab
Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of AKLIEF Cream vs vehicle cream.1 IGA=Investigator's Global Assessment.
Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of AKLIEF Cream vs vehicle cream.1 IGA=Investigator's Global Assessment.
See the visible impact of AKLIEF Cream on acne and acne-induced scarring
The clinical images presented are from a Phase 4 study evaluating the impact of AKLIEF Cream on acne-related scarring. AKLIEF Cream treats acne lesions, helping to reduce existing acne scars and prevent future scarring across all phototypes. Visible improvements in acne-induced scarring were observed as early as Week 2.2c
Phase 4 placebo controlled, 24 week split face trial2 IGA=Investigator’s Global Assessment; SGA =Scar Global Assessment.
Phase 4 placebo controlled, 24 week split face trial2 IGA=Investigator’s Global Assessment; SGA =Scar Global Assessment.
Phase 4 placebo controlled, 24 week split face trial2 IGA=Investigator’s Global Assessment; SGA =Scar Global Assessment.
See improvements in acne and acne-induced PIH with AKLIEF Cream
The images presented are from a Phase 4 clinical study evaluating the effect of AKLIEF Cream on acne-induced post-inflammatory hyperpigmentation (PIH)*. AKLIEF Cream rapidly reduced PIH severity in patients with acne during the first 12 weeks of treatment, with continued improvements in facial PIH observed through Week 24.3cd
Phase IV, randomized, placebo controlled study, to assess the efficacy of Aklief Cream in reducing PIH severity over 24 weeks vs vehicle cream.3 IGA= Investigator’s Global Assessment ODS= Overall Disease Severity PHAPI= post-acne hyperpigmentation index*
Phase IV, randomized, placebo controlled study, to assess the efficacy of Aklief Cream in reducing PIH severity over 24 weeks vs vehicle cream.3 IGA= Investigator’s Global Assessment ODS= Overall Disease Severity PHAPI= post-acne hyperpigmentation index*
Phase IV, randomized, placebo controlled study, to assess the efficacy of Aklief Cream in reducing PIH severity over 24 weeks vs vehicle cream.3 IGA= Investigator’s Global Assessment ODS= Overall Disease Severity PHAPI= post-acne hyperpigmentation index*
See what's possible with AKLIEF Cream combination therapy
The results and images presented are from a Phase 4 clinical study evaluating the effect of AKLIEF Cream in combination with oral doxycycline for severe acne vulgaris patients. AKLIEF Cream with oral doxycycline demonstrated greater IGA† success rates and lesion reductions compared with vehicle plus placebo.4abcd
Phase 4 double-blind, randomized, placebo and vehicle-controlled safety and efficacy 12-week study of AKLIEF Cream and oral doxycycline vs vehicle cream and placebo.4 IGA=Investigator's Global Assessment.
Phase 4 double-blind, randomized, placebo and vehicle-controlled safety and efficacy 12-week study of AKLIEF Cream and oral doxycycline vs vehicle cream and placebo.4 IGA=Investigator's Global Assessment.